Replies to post #214555 on Biotech Values

[DewDiligence]

GILD has NASH candidates with a few different MoAs. For FXR agonists, specifically, GILD's GS-9674 is ahead of ENTA's EDP-305, having started phase-2 for NASH in Oct 2016 (https://www.clinicaltrials.gov/ct2/show/NCT02854605 ).